Biotechnology company Panacea Biotec announced Q2FY27 results Consolidated Financial Highlights: Revenue from operations: In Q2FY27, consolidated revenue from operations stood at Rs 18,967 lakh, declining by 4.96% QoQ from Rs 19,957 lakh in Q1FY27 and increasing by 34.39% YoY from Rs 14,113 lakh in Q2FY26. For H1FY27, consolidated revenue from operations grew by 26.45% YoY to Rs 38,924 lakh compared to Rs 30,783 lakh in H1FY26. Total income: In Q2FY27, consolidated total income stood at Rs 19,627 lakh, registering a decline of 3.70% QoQ from Rs 20,381 lakh in Q1FY27 and a growth of 33.04% YoY from Rs 14,753 lakh in Q2FY26. For H1FY27, consolidated total income rose by 25.06% YoY to Rs 40,008 lakh from Rs 31,990 lakh in H1FY26. Profit before tax (PBT): In Q2FY27, consolidated PBT surged by 375.91% QoQ to Rs 1,699 lakh from Rs 357 lakh in Q1FY27, turning profitable YoY against a loss before tax of Rs 1,917 lakh in Q2FY26. For H1FY27, consolidated PBT turned positive at Rs 2,056 lakh compared to a loss before tax of Rs 1,261 lakh in H1FY26. Profit after tax (PAT): In Q2FY27, consolidated PAT jumped by 441.36% QoQ to Rs 1,191 lakh from Rs 220 lakh in Q1FY27, swinging to a profit YoY against a net loss of Rs 1,401 lakh in Q2FY26. For H1FY27, consolidated PAT stood at Rs 1,411 lakh compared to a net loss of Rs 1,005 lakh in H1FY26. Earnings per share (EPS): In Q2FY27, consolidated basic and diluted EPS rose by 400.00% QoQ to Rs 1.90 from Rs 0.38 in Q1FY27, improving YoY from a loss per share of Rs 2.27 in Q2FY26. For H1FY27, consolidated basic and diluted EPS stood at Rs 2.27 compared to a loss per share of Rs 1.62 in H1FY26. Standalone Financial Highlights: Revenue from operations: In Q2FY27, standalone revenue from operations stood at Rs 12,669 lakh, decreasing by 5.95% QoQ from Rs 13,471 lakh in Q1FY27 and increasing by 39.51% YoY from Rs 9,081 lakh in Q2FY26. For H1FY27, standalone revenue from operations increased by 28.73% YoY to Rs 26,140 lakh from Rs 20,306 lakh in H1FY26. Total income: In Q2FY27, standalone total income stood at Rs 13,310 lakh, declining by 5.45% QoQ from Rs 14,077 lakh in Q1FY27 and rising by 40.97% YoY from Rs 9,442 lakh in Q2FY26. For H1FY27, standalone total income grew by 29.42% YoY to Rs 27,387 lakh from Rs 21,162 lakh in H1FY26. Profit before tax (PBT): In Q2FY27, standalone PBT rose by 604.00% QoQ to Rs 1,408 lakh from Rs 200 lakh in Q1FY27, turning profitable YoY against a loss before tax of Rs 2,093 lakh in Q2FY26. For H1FY27, standalone PBT turned positive at Rs 1,608 lakh compared to a loss before tax of Rs 2,977 lakh in H1FY26. Profit after tax (PAT): In Q2FY27, standalone PAT surged by 673.38% QoQ to Rs 1,075 lakh from Rs 139 lakh in Q1FY27, swinging to a profit YoY from a net loss of Rs 1,564 lakh in Q2FY26. For H1FY27, standalone PAT reached Rs 1,214 lakh compared to a net loss of Rs 2,234 lakh in H1FY26. Earnings per share (EPS): In Q2FY27, standalone basic and diluted EPS rose by 665.22% QoQ to Rs 1.76 from Rs 0.23 in Q1FY27, improving YoY from a loss per share of Rs 2.55 in Q2FY26. For H1FY27, standalone basic and diluted EPS stood at Rs 1.98 compared to a loss per share of Rs 3.65 in H1FY26. Business & Segment-Wise Highlights: Vaccines segment: In Q2FY27, segment revenue stood at Rs 12,422 lakh, down 7.76% QoQ from Rs 13,467 lakh in Q1FY27 and up 36.79% YoY from Rs 9,081 lakh in Q2FY26, while H1FY27 segment revenue grew by 27.49% YoY to Rs 25,889 lakh from Rs 20,306 lakh in H1FY26. Formulations segment: In Q2FY27, segment revenue increased by 0.85% QoQ to Rs 6,545 lakh from Rs 6,490 lakh in Q1FY27 and grew by 30.07% YoY from Rs 5,032 lakh in Q2FY26, while H1FY27 segment revenue rose by 24.42% YoY to Rs 13,035 lakh from Rs 10,477 lakh in H1FY26. Result PDF